News

NCCN launches radiation therapy resource


 

Therapist preparing patient to receive radiation Photo by Rhoda Baer Photo by Rhoda Baer

Therapist preparing patient to receive radiation

The National Comprehensive Cancer Network® (NCCN®) recently launched the NCCN Radiation Therapy Compendium™, which provides a single access point for NCCN recommendations pertaining to radiation therapy.

The compendium provides guidance on all radiation therapy modalities recommended within NCCN guidelines, including intensity modulated radiation therapy, intra-operative radiation therapy, stereotactic radiosurgery/stereotactic body radiotherapy/stereotactic ablative radiotherapy, image-guided radiotherapy, low dose-rate brachytherapy/high dose-rate brachytherapy, radioisotope, and particle therapy.

“As a single source for all radiation therapy recommendations within the NCCN guidelines, the compendium benefits patients with cancer by assisting providers and payers in making evidence-based treatment and coverage decisions,” said Robert W. Carlson, MD, chief executive officer of NCCN.

The NCCN Radiation Therapy Compendium™ includes recommendations for the following 24 cancer types:

Acute myeloid leukemia

Anal cancer

B-cell lymphomas

Bladder cancer

Breast cancer

Chronic lymphocytic leukemia/small lymphoblastic lymphoma

Colon cancer

Hepatobiliary cancers

Kidney cancer

Malignant pleural mesothelioma

Melanoma

Multiple myeloma

Neuroendocrine tumors

Non-small cell lung cancer

Occult primary cancer

Pancreatic adenocarcinoma

Penile cancer

Primary cutaneous B-cell lymphomas

Prostate cancer

Rectal cancer

Small cell lung cancer

Soft tissue sarcoma

T-cell lymphomas

Testicular cancer

NCCN said additional cancer types will be published on a rolling basis over the coming months.

Recommended Reading

Auto-HCT patients run high risks for myeloid neoplasms
MDedge Hematology and Oncology
Advanced CLL treatment approach depends on comorbidity burden
MDedge Hematology and Oncology
Drug receives orphan designation for AML
MDedge Hematology and Oncology
Protein may prevent transformation from MDS to AML
MDedge Hematology and Oncology
ASCO reports progress, challenges in cancer care
MDedge Hematology and Oncology
Most blood cancer mutations due to DNA replication errors
MDedge Hematology and Oncology
New resource designed to help prevent CINV
MDedge Hematology and Oncology
AYAs struggle socially in early years after cancer diagnosis
MDedge Hematology and Oncology
Proteins may be therapeutic targets for TKI-resistant CML, ALL
MDedge Hematology and Oncology
New insight into high-hyperdiploid ALL
MDedge Hematology and Oncology